[Ambulatory therapy of trichomoniasis vaginalis. Clinical trial of a new Trichomonas-active azide substance].
Report on the results of the clinical trial of a new trichomonacide in ambulatory patients in a gynaecological practice. A report is given on a new drug for the treatment of vaginal trichomoniasis, which has been tried in 87 patients of a gynaecological practice under outpatient conditions. The rate of failures was 5.7% (5 of 87 cases). The advantages over alternative preparations is to be seen in the short duration of treatment (24 hours at the most), and in the favourable tolerance in spite of high doses.
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000994:Antitrichomonal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001386:Azides / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008875:Middle Aged; D009593:Nitroimidazoles / Q000627:therapeutic use*; D009950:Ornidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014247:Trichomonas Vaginitis / Q000188:drug therapy*
D000994:Antitrichomonal Agents; D001386:Azides; D009593:Nitroimidazoles; D009950:Ornidazole
Ambulante Therapie der Trichomoniasis vaginalis. Erfahrungsbericht über Ergebnisse der klinischen Prüfung einer neuen trichomonazid-wirksamen Substanz.